| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 3.56 | 126.8% |
| Total Income | 3.56 | 126.8% |
| Expenditure | 49.46 | 4.7% |
| PBT | -53.05 | 23.0% |
| Net Profit | -53.54 | 22.7% |
| OPM | — | |
| NPM | — | |
| EPS | -0.85 | 3.7% |
uniQure Reports Q1 2026 Financial Results
05 May 2026 · 5 May, 4:42 pm
Summary
uniQure N.V. reported its financial results for the first quarter of 2026, highlighting progress across its business. The company's cash, cash equivalents, and current investment securities totaled $586.6 million as of March 31, 2026. Revenue for the quarter was $3.6 million, compared to $1.6 million in the same period in 2025. The company is advancing AMT-130 for Huntington’s disease and expects to submit an MAA in the third quarter of 2026.
Key Highlights
- 1
uniQure held a Type A meeting with the FDA in January 2026 to discuss the regulatory path forward for AMT-130.
- 2
A Type B meeting with the FDA has been granted to discuss a potential new clinical trial design and statistical analysis plan for AMT-130's four-year data expected in Q3 2026.
- 3
The company expects to submit a Marketing Authorization Application (MAA) for AMT-130 to the UK MHRA in the third quarter of 2026.
- 4
Enrollment is ongoing in the second dose cohort of the Phase I/IIa study for AMT-260, expected to be completed in mid-2026.
- 5
uniQure presented updated data from the AMT-191 Phase I/II study in Fabry disease, showing sustained increases in α-Gal A Enzyme Activity and stable Lyso-Gb3 levels.
- 6
As of March 31, 2026, uniQure had $586.6 million in cash, cash equivalents, and current investment securities, providing a runway into the second half of 2029.
- 7
Revenue for the three months ended March 31, 2026 was $3.6 million, compared to $1.6 million in the same period in 2025.
Management Comments
Matthew Kapusta
During the first quarter of 2026, we remained focused on advancing AMT-130 to patients globally as rapidly as possible while executing across our broader pipeline. We believe our data continue to support the potential for AMT-130 to fundamentally change the treatment landscape for Huntington’s disease, and we look forward to continued engagement with the FDA. In parallel, following a constructive interaction with the MHRA, we are preparing to submit an MAA in the third quarter and evaluating additional international opportunities. We expect to deliver key clinical updates throughout 2026, including data from our AMT-260 program in refractory mesial temporal lobe epilepsy later in the second quarter and four-year AMT-130 data analysis in the third quarter. With these important milestones ahead, we remain committed to advancing our programs with urgency while maintaining disciplined capital allocation to drive long-term shareholder value.
Informational and educational content only. Not investment advice.